Co-Administration of Highly Protein-Bound Drugs
When two highly protein-bound drugs are administered simultaneously, one drug can displace the other from plasma protein binding sites, transiently increasing the free (unbound) concentration of the displaced drug, which may lead to enhanced pharmacologic effects or toxicity—however, this interaction is rarely clinically significant in isolation and typically requires additional mechanisms (such as enzyme inhibition or induction) to produce meaningful clinical consequences. 1, 2
Mechanism of Protein Displacement
Protein displacement occurs when drugs compete for the same binding sites on plasma proteins, primarily albumin (for acidic drugs) and α1-acid glycoprotein (AGP) (for basic drugs). 3, 4
The displaced drug experiences a temporary increase in its free fraction, which is the pharmacologically active form that can distribute to tissues and interact with receptors. 5, 4
However, compensatory mechanisms rapidly buffer this effect: the increased free drug undergoes enhanced hepatic metabolism and renal clearance, typically restoring equilibrium within hours to days. 3, 2
Clinical Significance: Generally Overestimated
Simple protein displacement interactions are rarely clinically significant on their own because the body's compensatory clearance mechanisms quickly normalize free drug concentrations. 2
Clinically important interactions attributed to protein displacement almost always involve additional mechanisms, particularly inhibition or induction of cytochrome P450 (CYP) enzymes. 1, 3
Key Examples Where Displacement Matters (With Additional Mechanisms):
Warfarin Interactions:
Phenytoin initially displaces warfarin from protein binding sites, transiently potentiating bleeding effects. However, phenytoin subsequently induces CYP450 enzymes, ultimately requiring higher warfarin doses to maintain therapeutic INR—this is a biphasic interaction. 1
Paclitaxel potentiates warfarin anticoagulation by displacing it from protein binding sites, contributing to increased bleeding risk. 1
NSAIDs increase bleeding risk with warfarin through both protein displacement AND pharmacodynamic effects (antiplatelet activity and GI mucosal injury), doubling the risk of bleeding compared to warfarin alone. 1
Statins (atorvastatin, rosuvastatin, simvastatin) interact with warfarin through a combination of protein displacement PLUS CYP3A4 inhibition, increasing unbound warfarin concentrations. 1
Other Notable Examples:
GDC-0449 competitively inhibits RO4929097 binding to AGP, increasing the free fraction by 3.7-fold and significantly decreasing total (but not unbound) drug exposure. 5
Ivacaftor (>97% protein-bound) can experience clinically significant interactions with docusate, montelukast, ibuprofen, dicloxacillin, omeprazole, and loratadine due to competition for HSA and AGP binding sites. 6
Factors That Increase Risk of Clinically Significant Interactions
High-risk scenarios include:
Drugs with >90% protein binding AND narrow therapeutic indices (e.g., warfarin, phenytoin, digoxin). 3, 4
Drugs eliminated primarily through a single metabolic pathway that is also inhibited or induced by the co-administered drug. 7
Disease states that alter protein levels: hypoalbuminemia (malnutrition, liver disease, nephrotic syndrome), elevated AGP (acute inflammation, myocardial infarction, cancer), or renal failure. 4
Stress conditions and elevated free fatty acids (FFAs), which can displace acidic drugs like ampicillin from albumin, potentially causing seizures or other toxicity. 4
Clinical Management Algorithm
When prescribing two highly protein-bound drugs:
Assess for additional interaction mechanisms (CYP450 inhibition/induction, P-glycoprotein effects, pharmacodynamic interactions). 1
If additional mechanisms are present:
For drugs with narrow therapeutic indices:
Consider alternative agents with lower protein binding or different binding sites when feasible. 7
Common Pitfalls to Avoid
Do not assume protein displacement alone will cause toxicity—look for concurrent enzyme inhibition/induction or pharmacodynamic interactions. 2
Do not rely solely on total drug concentrations for highly protein-bound drugs during interactions; unbound concentrations are more clinically relevant. 5
Do not overlook disease-related changes in protein binding (inflammation increases AGP; liver/kidney disease decreases albumin), which can amplify displacement interactions. 4
Recognize that the timing of drug initiation matters: adding an interacting drug to stable therapy poses greater risk than starting both drugs simultaneously with appropriate monitoring. 1